SENZA — SenzaGen AB Income Statement
0.000.00%
- SEK189.42m
- SEK165.80m
- SEK57.70m
- 46
- 16
- 71
- 36
Annual income statement for SenzaGen AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.96 | 15.4 | 41.8 | 49.9 | 57.7 |
| Cost of Revenue | |||||
| Gross Profit | 5.58 | 9.45 | 27.3 | 34.9 | 38.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 35.1 | 47 | 66.9 | 72.4 | 76.6 |
| Operating Profit | -27.1 | -31.5 | -25.1 | -22.5 | -18.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -27.2 | -31.4 | -25 | -22 | -18.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -27.2 | -31.3 | -24.9 | -22.1 | -17.9 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -27.2 | -31.3 | -24.9 | -22.1 | -17.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -27.2 | -31.3 | -24.9 | -22.1 | -17.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.27 | -1.35 | -0.823 | -0.576 | -0.312 |
| Dividends per Share |